The committee's work this session has been dominated by two overlapping threads: a study of pharmaceutical sovereignty and a running investigation into the terminated PrescribeIT e-prescribing program. On sovereignty, witnesses from industry, patient groups, academia, pharmacy and research organizations have repeatedly described Canada as heavily import-dependent—68% of drugs imported, 83% of production abroad, only about 2% of active pharmaceutical ingredients made domestically, and over 2,000 shortages reported annually. Recurring recommendations include designating critical medicines (insulin, sterile injectables, antimicrobials), prioritizing supply resilience over lowest price in procurement, "buy Canadian" preferences for hospital and public drug plans, faster and more predictable regulatory pathways, incentives to match foreign offers, and better shortage data. Witnesses disagreed about scope and emphasis: some framed sovereignty primarily as manufacturing and supply chain security, while others argued it must also mean domestic innovation, timely access to new therapies, or the "last mile" of pharmacy distribution. Addiction policy produced sharper conflict, with one witness calling safe supply an "unmitigated failure" and others defending harm reduction and supervised consumption as life-saving and complementary to treatment.

The PrescribeIT study has generated the most procedural friction. Witnesses from Telus Health, Canada Health Infoway and Health Canada gave differing figures for total federal investment—$98 million to Telus, $250 million and $298 million cited as totals—and differing accounts of who decided to wind the program down, though all agreed prescriber adoption stayed under 5% of prescriptions and that the 75% sustainability target was not met. Infoway and Telus both characterized the platform as a technical success undermined by the absence of provincial mandates and workflow irritants, while the department pointed to a 2023 assessment that the program would not become self-sustaining. Members have repeatedly moved for Auditor General audits, production of unredacted documents, and appearances by the Minister of Health and former Infoway CEO Michael Green, with debate frequently adjourned or interrupted before decisions were reached.

Other subjects have drawn testimony from a wide range of federal bodies and stakeholders: the Canadian Food Inspection Agency and the Public Health Agency of Canada (including the postponed Longueuil laboratory closure, measles elimination status, and vaccine hesitancy), the Canadian Centre on Substance Use and Addiction, the Canadian Dental Care Plan, Grifols' plasma partnership with Canadian Blood Services, and supplementary estimates featuring the Health Minister and senior officials from Health Canada, CFIA, CIHR and PHAC. Constituencies heard from include patient coalitions, generic and innovative drug manufacturers, pharmacy distributors and associations, health charities, academic researchers, clinicians, and provincial industry groups such as Médicament Québec. A recurring theme across these appearances is federal-provincial coordination and data-sharing, whether on drug pricing, public health surveillance, clinical trials or digital health.

Over time the committee's attention has shifted from substantive witness panels toward procedural conflict. Earlier meetings in March and April 2026 featured dense panels on sovereignty and the CCSA; by late April and May, meetings were consumed by motions for documents, challenges to the chair's rulings, motions to adjourn debate, and competing Liberal and Conservative motions over PrescribeIT, the dental plan and Grifols. The committee elected a new chair in late April and vice-chairs in mid-June, and several motions were adopted by unanimous consent—including requests for CFIA and PHAC appearances, Grifols-related reports, and routine membership provisions—but numerous substantive motions remained unresolved on the record, and the session's final meeting dealt only with the vice-chair elections.